![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 11
Zeitschriftenartikel
Stolze, T.; Franke, S.; Haybaeck, J.; Moehler, M.; Grimminger, P. P.; Lang, H.; Roth, W.; Gockel, I.; Kreuser, N.; Blaker, H.; Wittekind, C.; Lordick, F.; Vieth, M.; Veits, L.; Waidmann, O.; Lingohr, P.; Peitz, U.; Schildberg, C.; Kruschewski, M.; Vassos, N.; Goni, E.; Bruns, C. J.; Ridwelski, K.; Wolff, S.; Lippert, H.; Schumacher, J.; Malfertheiner, P. und Venerito, M.
(2022):
Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 3: S. 1007-1017
Garlipp, B.; Gibbs, P.; Van Hazel, G. A.; Jeyarajah, R.; Martin, R. C. G.; Bruns, C. J.; Lang, H.; Manas, D. M.; Ettorre, G. M.; Pardo, F.; Donckier, V.; Benckert, C.; van Gulik, T. M.; Goere, D.; Schön, M.; Pratschke, J.; Bechstein, W. O.; de la Cuesta, A. M.; Adeyemi, S.; Ricke, J. und Seidensticker, M.
(2019):
Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial.
In: British Journal of Surgery, Bd. 106, Nr. 13: S. 1837-1846
Modest, Dominik P.; Denecke, Timm; Pratschke, J.; Ricard, Ingrid; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Modest, H. I.; Held, S.; Folprecht, Gunnar; Heinemann, Volker und Neumann, Ulf Peter
(2017):
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
In: European Journal of Cancer, Bd. 88: S. 77-86
Modest, D. P.; Denecke, T.; Pratschke, J.; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Stintzing, S.; Modest, H. I.; Held, S.; Folprecht, G.; Heinemann, V. und Neumann, U. P.
(2017):
Central evaluation for surgical treatment options in FIRE-3-updated results and impact on overall survival.
In: Oncology Research and Treatment, Bd. 40: S. 122
Neumann, U.; Denecke, T.; Pratschke, J.; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Folprecht, G.; Stintzing, S.; Held, S.; Heinemann, V. und Modest, D. P.
(2016):
Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) - a retrospective, central evaluation of FIRE-3.
In: Annals of Oncology, Bd. 27
Sen Gupta, A.; Zhao, Y.; Qin, J.; Augsburger, D.; Zhao, L.; Camaj, P.; Wang, Y.; Nelson, P. und Bruns, C. J.
(2016):
Pilot results on effects of human hMSC in an orthotopic SCID/NOD mouse model for cholangiocarcinoma.
In: Oncology Research and Treatment, Bd. 39: S. 41
Modest, D. P.; Camaj, P.; Heinemann, V.; Schwarz, B.; Jung, A.; Laubender, Rüdiger P.; Gamba, S.; Haertl, C.; Stintzing, S.; Primo, S. und Bruns, C. J.
(2013):
KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 6: S. 953-961
Haas, M.; Heinemann, V.; Kullmann, F.; Laubender, Rüdiger P.; Klose, C.; Bruns, C. J.; Holdenrieder, S.; Modest, D. P.; Schulz, C. und Boeck, S.
(2013):
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 4: S. 681-689
Kriegl, L.; Jung, A.; Engel, Jutta; Jackstadt, R.; Gerbes, A. L.; Gallmeier, E.; Reiche, J. A.; Hermeking, H.; Rizzani, A.; Bruns, C. J.; Kolligs, F. T.; Kirchner, T.; Göke, Burkhard und de Toni, E. N.
(2010):
Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma.
In: Clinical Cancer Research, Bd. 16, Nr. 22: S. 5529-5538
Boeck, S.; Haas, M.; Laubender, Rüdiger P.; Kullmann, F.; Klose, C.; Bruns, C. J.; Wilkowski, R.; Stieber, P.; Holdenrieder, S.; Buchner, Hannes; Mansmann, Ulrich und Heinemann, V.
(2010):
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
In: Clinical Cancer Research, Bd. 16, Nr. 3: S. 986-994
Haas, M.; Laubender, Rüdiger P.; Stieber, P.; Holdenrieder, S.; Bruns, C. J.; Wilkowski, R.; Mansmann, Ulrich; Heinemann, V. und Boeck, S.
(2010):
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
In: Tumor Biology, Bd. 31, Nr. 4: S. 351-357